scholarly journals Oncogenic and incidental HPV types associated with histologically confirmed cervical intraepithelial neoplasia in HIV-positive and HIV-negative South African women

2016 ◽  
Vol 106 (6) ◽  
pp. 617 ◽  
Author(s):  
Matthys Cornelis Van Aardt ◽  
Greta Dreyer ◽  
Leon Cornelius Snyman ◽  
Karin Louise Richter ◽  
Piet Becker ◽  
...  
Viruses ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 280
Author(s):  
Ongeziwe Taku ◽  
Zizipho Z. A. Mbulawa ◽  
Keletso Phohlo ◽  
Mirta Garcia-Jardon ◽  
Charles B. Businge ◽  
...  

South African women have a high rate of cervical cancer cases, but there are limited data on human papillomavirus (HPV) genotypes in cervical intraepithelial neoplasia (CIN) in the Eastern Cape province, South Africa. A total of 193 cervical specimens with confirmed CIN from women aged 18 years or older, recruited from a referral hospital, were tested for HPV infection. The cervical specimens, smeared onto FTA cards, were screened for 36 HPV types using an HPV direct flow kit. HPV prevalence was 93.5% (43/46) in CIN2 and 96.6% (142/147) in CIN3. HIV-positive women had a significantly higher HPV prevalence than HIV-negative women (98.0% vs. 89.1%, p = 0.012). The prevalence of multiple types was significantly higher in HIV-positive than HIV-negative women (p = 0.034). The frequently detected genotypes were HPV35 (23.9%), HPV58 (23.9%), HPV45 (19.6%), and HPV16 (17.3%) in CIN2 cases, while in CIN3, HPV35 (22.5%), HPV16 (21.8%), HPV33 (15.6%), and HPV58 (14.3%) were the most common identified HPV types, independent of HIV status. The prevalence of HPV types targeted by the nonavalent HPV vaccine was 60.9% and 68.7% among women with CIN2 and CIN3, respectively, indicating that vaccination would have an impact both in HIV-negative and HIV-positive South African women, although it will not provide full protection in preventing HPV infection and cervical cancer lesions.


2003 ◽  
Vol 71 (2) ◽  
pp. 265-273 ◽  
Author(s):  
Patti Kay ◽  
Robbert Soeters ◽  
James Nevin ◽  
Lynette Denny ◽  
Catherine M.C. Dehaeck ◽  
...  

2013 ◽  
Vol 17 (7) ◽  
pp. 1603-1613 ◽  
Author(s):  
Stephanie V Wrottesley ◽  
Lisa K Micklesfield ◽  
Matthew M Hamill ◽  
Gail R Goldberg ◽  
Ann Prentice ◽  
...  

AbstractObjectiveThe present paper examines dietary intake and body composition in antiretroviral (ARV)-naïve HIV-positive compared with HIV-negative South African women, as well as the impact of disease severity on these variables.DesignBaseline data from a longitudinal study assessing bone health in HIV-negative and HIV-positive premenopausal South African women over 18 years of age were used. Anthropometry and body composition, measured by dual energy X-ray absorptiometry, were analysed together with dietary intake data assessed using an interviewer-based quantitative FFQ.SettingSoweto, Johannesburg, South Africa.SubjectsBlack, urban South African women were divided into three groups: (i) HIV-negative (HIV−; n 98); (ii) HIV-positive with preserved CD4 counts (HIV+ non-ARV; n 74); and (iii) HIV-positive with low CD4 counts and due to start ARV treatment (HIV+ pre-ARV; n 75).ResultsThe prevalence of overweight and obesity was high in this population (59 %). The HIV+ pre-ARV group was lighter and had a lower BMI than the other two groups (all P < 0·001). HIV+ pre-ARV women also had lower fat and lean masses and percentage body fat than their HIV− and HIV+ non-ARV counterparts. After adjustment, there were no differences in macronutrient intakes across study groups; however, fat and sugar intakes were high and consumption of predominantly refined food items was common overall.ConclusionHIV-associated immunosuppression may be a key determinant of body composition in HIV-positive women. However, in populations with high obesity prevalence, these differences become evident only at advanced stages of infection.


2011 ◽  
Vol 10 (3) ◽  
pp. 248-264 ◽  
Author(s):  
Dorina Onoya ◽  
Priscilla Reddy ◽  
Sibusiso Sifunda ◽  
Gina M. Wingood ◽  
Bart van den Borne ◽  
...  

2008 ◽  
Vol 104 (2) ◽  
pp. 100-104 ◽  
Author(s):  
Maria Inês Lima ◽  
Alexandre Tafuri ◽  
Angela C Araújo ◽  
Luiza de Miranda Lima ◽  
Victor Hugo Melo

2011 ◽  
Vol 51 (6) ◽  
pp. 546-565 ◽  
Author(s):  
Jonathan P. Mundell ◽  
Maretha J. Visser ◽  
Jennifer D. Makin ◽  
Trace S. Kershaw ◽  
Brian W. C. Forsyth ◽  
...  

2017 ◽  
Vol 94 (1) ◽  
pp. 55-61 ◽  
Author(s):  
Lynette J Menezes ◽  
Ubin Pokharel ◽  
Staci L Sudenga ◽  
Matthys H Botha ◽  
Michele Zeier ◽  
...  

ObjectiveTo estimate the prevalence and describe the patterns of concurrent human papillomavirus (HPV) and STIs and associated factors among HIV-negative young Western Cape, South African women participating in the Efficacy of HPV Vaccine to Reduce HIV Infection (EVRI) trial.MethodsHIV-negative women aged 16–24 years old were enrolled in the EVRI trial (NCT01489527) and randomised to receive the licensed four-valent HPV vaccine or placebo. At study entry, participants were clinically evaluated for five STIs: herpes simplex virus type 2 (HSV-2), chlamydia, gonorrhoea, syphilis and disease-causing HPV genotypes (6/11/16/18/31/33/35/39/45/51/52/56/58/59/68). Demographic and sexual history characteristics were compared among women with STI co-infections, single infection and no infection using Pearson χ2 and Mann-Whitney tests. ORs were calculated to evaluate factors associated with STI co-infection prevalence.ResultsAmong 388 young women, STI co-infection prevalence was high: 47% had ≥2 concurrent STIs, 36% had a single STI and 17% had none of the five evaluated STIs. HPV/HSV-2 (26%) was the most prevalent co-infection detected followed by HPV/HSV-2/Chlamydia trachomatis (CT) (17%) and HPV/CT (15%). Co-infection prevalence was independently associated with alcohol use (adjusted OR=2.01, 95% CI 1.00 to 4.06) and having a sexual partner with an STI (adjusted OR=6.96, 95% CI 1.53 to 30.08).ConclusionsAmong high-risk young women from underserved communities such as in Southern Africa, a multicomponent prevention strategy that integrates medical and behavioural interventions targeting both men and women is essential to prevent acquisition of concurrent STI infections and consequent disease.Trial registration numberNCT01489527; Post-results.


Cytopathology ◽  
2001 ◽  
Vol 12 (2) ◽  
pp. 84-93 ◽  
Author(s):  
M. Branca ◽  
E. Rossi ◽  
M. Alderisio ◽  
G. Migliore ◽  
P. L. Morosini ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document